Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies
International Journal of Molecular Sciences · 19.04.2023 · 24 (8) · 7481
DOI: 10.3390/ijms24087481 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.04.2023. Verfasst von Xuan-Thanh-An Nguyen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. Hauptthemen laut MEDLINE: Retinitis Pigmentosa, Night Blindness, Retinal Dystrophies. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 351 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Retinitis pigmentosa (RP) comprises a group of inherited retinal dystrophies characterized by the degeneration of rod photoreceptors, followed by the degeneration of cone photoreceptors. As a result of photoreceptor degeneration, affected individuals experience gradual loss of visual function, with primary symptoms of progressive nyctalopia, constricted visual fields and, ultimately, central vision loss. The onset, severity and clinical course of RP shows great variability and unpredictability, with most patients already experiencing some degree of visual disability in childhood. While RP is currently untreatable for the majority of patients, significant efforts have been made in the development of genetic therapies, which offer new hope for treatment for patients affected by inherited retinal dystrophies. In this exciting era of emerging gene therapies, it remains imperative to continue supporting patients with RP using all available options to manage their condition. Patients with RP experience a wide variety of physical, mental and social-emotional difficulties during their lifetime, of which some require timely intervention. This review aims to familiarize readers with clinical management options that are currently available for patients with RP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
- Department of Ophthalmology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.
- Department of Clinical Genetics, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
- Bartiméus, Diagnostic Center for Complex Visual Disorders, 3703 AJ Zeist, The Netherlands.
- Department of Ophthalmology, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
ORCID-Profile: Xuan-Thanh-An Nguyen, Lude Moekotte, Astrid S Plomp
Zitieren
APA
Nguyen, X. T., Moekotte, L., Plomp, A. S., Bergen, A. A., van Genderen, M. M., & Boon, C. J. F. (2023). Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies. International Journal of Molecular Sciences, 24(8), 7481. https://doi.org/10.3390/ijms24087481
Vancouver
Nguyen XT, Moekotte L, Plomp AS, Bergen AA, van Genderen MM, Boon CJF. Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies. International Journal of Molecular Sciences. 2023;24(8):7481. doi:10.3390/ijms24087481
BibTeX
@article{Nguyen2023,
author = {Nguyen, Xuan-Thanh-An and Moekotte, Lude and Plomp, Astrid S and Bergen, Arthur A and van Genderen, Maria M and Boon, Camiel J F},
title = {Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {8},
pages = {7481},
doi = {10.3390/ijms24087481}
}
EUVIMED